Edition:
United States

AstraZeneca PLC (AZN.N)

AZN.N on New York Stock Exchange

32.67USD
19 Sep 2017
Change (% chg)

$0.25 (+0.77%)
Prev Close
$32.42
Open
$32.75
Day's High
$32.83
Day's Low
$32.61
Volume
724,663
Avg. Vol
815,621
52-wk High
$35.60
52-wk Low
$25.56

Latest Key Developments (Source: Significant Developments)

Flexion Therapeutics says co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​
Thursday, 14 Sep 2017 04:48pm EDT 

Sept 15 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics Inc - ‍on September 8, co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​.Flexion Therapeutics Inc - ‍out-license agreement related to co's FX005 sustained-release p38 MAP.Flexion Therapeutics Inc - ‍pursuant to terms of out-license agreement, termination will be effective three months after company's delivery of notice​.Flexion Therapeutics Inc - ‍upon termination of out-license agreement, Flexion's license rights pertaining to FX005 will revert to Astrazeneca​.Flexion Therapeutics Inc - ‍upon termination of out-license agreement Flexion's milestone, royalty and patent maintenance obligations under agreement will cease.​.  Full Article

Astrazeneca says Aspen acquires remaining rights to AZ anaesthetics
Thursday, 14 Sep 2017 02:00am EDT 

Sept 14 (Reuters) - Astrazeneca Plc ::ASPEN ACQUIRES REMAINING RIGHTS TO AZ ANAESTHETICS.ENTERED AGREEMENT WITH ASPEN GLOBAL; AGI TO ACQUIRE RESIDUAL RIGHTS TO ESTABLISHED ANAESTHETIC MEDICINES.UUNDER NEW AGREEMENT, AGI WILL NO LONGER PAY ROYALTIES TO ASTRAZENECA​.AGI TO BUY REMAINING RIGHTS TO INTELLECTUAL PROPERTY; MANUFACTURING KNOW- HOW RELATED TO ANAESTHETIC MEDICINES FOR UPFRONT CONSIDERATION OF $555 MILLION.‍NEW, ADDITIONAL AGREEMENT IS EXPECTED TO CLOSE IN Q4 OF 2017, DOES NOT IMPACT ASTRAZENECA'S FINANCIAL GUIDANCE FOR 2017​.AGI TO PAY ASTRAZENECA UP TO $211 MLN IN PERFORMANCE-RELATED MILESTONES BASED ON SALES; GROSS MARGIN DURING PERIOD FROM 1 SEPT TO 30 NOV 2019.ASTRAZENECA WILL CONTINUE TO MANUFACTURE AND SUPPLY MEDICINES TO AGI DURING A TRANSITION PERIOD OF UP TO FIVE YEARS.  Full Article

Celgene provides update on the Fusion clinical program
Thursday, 7 Sep 2017 07:30am EDT 

Sept 7 (Reuters) - Celgene Corp :Celgene provides update on the Fusion clinical program.‍Patients enrolled in trials on partial clinical hold who are receiving clinical benefit from treatment as determined by investigator,may remain on treatment​.‍U.S. FDA has placed a partial clinical hold on five trials and a full clinical hold on one trial in celgene fusion program​.‍FDA has placed a partial clinical hold on five trials and a full clinical hold on one trial in celgene Fusion program​.‍Patients enrolled in trial on full clinical hold will be discontinued from treatment​.FDA decision based on risks identified in trials for pembrolizumab in patients with multiple myeloma in combination with immunomodulatory agents​.‍Clinical holds allow for additional information to be collected to further understand risk benefit profile of program​.‍No new patients will be enrolled into trials placed on hold​.‍Trial placed on full clinical hold is MEDI4736-MM-002​.  Full Article

Almirall announces phase III positive Duaklir results for COPD
Thursday, 7 Sep 2017 03:36am EDT 

Sept 7 (Reuters) - ALMIRALL SA ::SAYS PHASE III STUDY SHOWS DUAKLIR SIGNIFICANTLY IMPROVES LUNG FUNCTION IN MODERATE TO VERY SEVERE STABLE COPD.TO GET SALES-RELATED MILESTONES FROM ASTRAZENECA ASSOCIATED TO DUAKLIR SALES IN US, ACCORDING TO GLOBAL COLLABORATION BETWEEN BOTH COMPANIES.  Full Article

AstraZeneca has no comment on report it sought to buy Daiichi Sankyo
Thursday, 31 Aug 2017 02:43am EDT 

Aug 31 (Reuters) - AstraZeneca Plc :Britain's AstraZeneca has no comment on report it sought to buy Japan's Daiichi Sankyo <<<4568.T>>> last year - spokeswoman.  Full Article

AstraZeneca, Takeda collaborate to develop, commercialise MEDI1341 for Parkinson's disease
Tuesday, 29 Aug 2017 02:05am EDT 

Aug 29 (Reuters) - AstraZeneca Plc :ASTRAZENECA AND TAKEDA ESTABLISH COLLABORATION TO DEVELOP AND COMMERCIALISE MEDI1341 FOR PARKINSON'S DISEASE.PARTIES ENTERS DEAL TO DEVELOP, COMMERCIALISE MEDI1341, ALPHA-SYNUCLEIN ANTIBODY CURRENTLY IN DEVELOPMENT AS POTENTIAL TREATMENT FOR PARKINSON'S DISEASE.  Full Article

Astrazeneca says U.S. FDA approves Faslodex
Monday, 28 Aug 2017 07:00am EDT 

Aug 28 (Reuters) - Astrazeneca Plc ::FASLODEX® (FULVESTRANT) RECEIVES US FDA APPROVAL AS MONOTHERAPY FOR EXPANDED USE IN HR+, HER2- ADVANCED BREAST CANCER.FDA APPROVAL IS BASED ON PIVOTAL DATA FROM PHASE III FALCON TRIAL.  Full Article

Perrigo announces final FDA approval and settlement for the store brand OTC equivalent of Nexium 24hr capsules
Monday, 21 Aug 2017 09:01am EDT 

Aug 21 (Reuters) - Perrigo Company Plc :Perrigo announces final FDA approval and settlement for the store brand OTC equivalent of Nexium 24hr capsules.‍Received final approval from U.S. Food & drug administration for store brand OTC equivalent of nexium 24hr capsules​.Says ‍product will be packaged and marketed as store brand or retailer 'own label' brand​.‍Reached settlement of patent litigation with Astrazeneca allowing store brand OTC equivalent of Nexium 24hr capsules to launch in late Sept..  Full Article

Champions Oncology announces strategic collaboration with AstraZeneca to develop unique cohorts of PDX models
Monday, 21 Aug 2017 08:30am EDT 

Aug 21 (Reuters) - Champions Biotechnology Inc :Champions Oncology announces strategic collaboration with AstraZeneca to develop unique cohorts of patient-derived xenograft (PDX) models.Champions Biotechnology Inc- ‍cohorts of PDX models will be used in AstraZeneca's Oncology research and development programs in breast and lung cancer​.  Full Article

AstraZeneca hires two immuno-oncology experts
Monday, 31 Jul 2017 08:30am EDT 

July 31 (Reuters) - AstraZeneca Plc ::‍Jean-Charles Soria joins Medimmune, co's global biologics research and development arm, as senior vice president, head of oncology innovative medicines.Geoffrey Kim appointed head oncology strategic combinations at AstraZeneca​.  Full Article

France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus

PARIS French biotech company Neovacs is confident that its experimental drug to treat lupus could grab significant market share from standard treatments of the auto-immune disease, its chief executive said.